Bonnie G Su1,2,3, Matthew J Henley1,2
1David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, United States.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Transcription factors (TFs) present unique drug discovery challenges due to their inherent structural disorder, termed "fuzziness." This summary explores how biophysical and chemical biology methods can overcome these obstacles for TF-targeted therapeutics.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: